GLIMEPIRIDE 2mg. IP + PIOGLITAZONE 15mg. IP + METFORMIN 500mg. IP

A triple-drug combination of glucose-lowering drugs that treat high blood sugar levels caused by type 2 diabetes An alternative to other sulphonylureas in patients with type 2 diabetes mellitus not well controlled by diet alone. (H D Langtry, 1998) Significantly reduces the levels of triglyceride, low-density lipoproteins, and total cholesterol in type 2 diabetes patients. (D M Meshram, 2005) A promising therapeutic strategy that is effective in addressing both pathophysiological defects of type 2 diabetes mellitus. (Giuseppe Derosa, 2009) A valuable therapeutic tool in the prevention of cardiovascular events in type 2 diabetic patients with microalbuminuria and renal impairment. (Giuseppe Derosa, 2009) A suitable treatment option not only for optimizing management of glycemic control but also for prevention of the cardiovascular complications of diabetes. (Salvadeo, 2007) A choice of drug for insulin-resistant type 2 diabetes mellitus patients having dyslipidemia, hypertension, or a history of cardiovascular disease. (Fahmida Alam, 2019) An effective agent in achieving glycemic control and ameliorating lipid profile in type 2 diabetes mellitus. (Giuseppe Derosa, 2009) A promising alternative in type 2 diabetic patients at high cardiovascular risk. (Giuseppe Derosa, 2009)